Cormorant Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Cormorant Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-150,000	Closed	-$7.95M	–	46
2025 Q1	$7.95M	Sell	150,000 -250,000	-63%	-$13.9M	0.6%	31
2024 Q4	$22.4M	Hold	400,000	–	–	1.23%	23
2024 Q3	$21M	Sell	400,000 -75,000	-16%	-$3.59M	1.11%	28
2024 Q2	$19.5M	Sell	475,000 -75,000	-14%	-$2.99M	1.13%	27
2024 Q1	$23.8M	Hold	550,000	–	–	1.05%	30
2023 Q4	$25.3M	Sell	550,000 -300,000	-35%	-$9.46M	1.21%	26
2023 Q3	$19.5M	Buy	850,000 +250,000	+42%	+$5.6M	1.14%	24
2023 Q2	$9.89M	Buy	+600,000	New	+$10.8M	0.55%	40

Other funds holding RYTM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cormorant Asset Management's RYTM Position: Q2 2025 in Review

Cormorant Asset Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2025, closing a stake of 150,000 shares — an estimated $7.95M sold.

Cormorant Asset Management first reported a position in RYTM in Q2 2023 and held it in 8 quarters. The position peaked at $25.3M in Q4 2023. 227 funds tracked by Wall St. Rank hold RYTM as of Q2 2025.

Cormorant Asset Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Cormorant Asset Management sold 150,000 Rhythm Pharmaceuticals shares in Q2 2025, an estimated $7.95M.
Cormorant Asset Management first reported a position in Rhythm Pharmaceuticals in Q2 2023 and held it in 8 quarters.
Cormorant Asset Management's Rhythm Pharmaceuticals position peaked at $25.3M in Q4 2023.
227 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2025.

Based on Cormorant Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.